The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Current issues in non‐inferiority trials
Abstract
Non‐inferiority (NI) trials enable a direct comparison of the relative benefit‐to‐risk profiles of an experimental intervention and a standard‐of‐care regimen. When the standard has clinical efficacy of substantial magnitude that is precisely estimated ideally using data from multiple adequate and well‐controlled trials, with such estimates being relevant to the setting of the NI trial, then the NI trial can provide the scientific and regulatory evidence required to reliably assess the efficacy of the new intervention. In clinical practice, considerable uncertainty remains regarding when such trials should be conducted, how they should be designed, what standards for quality of trial conduct must be achieved, and how results should be interpreted. Recent examples will be considered to provide important insights and to highlight some of the challenges that remain to be adequately addressed regarding the use of the NI approach for the evaluation of new interventions. ‘Imputed placebo’ and ‘margin’‐based approaches to NI trial design will be considered, as well as the risk of ‘bio‐creep’ with repeated NI trials, use of NI trials when determining whether excess safety risks can be ruled out, higher standards regarding quality of study conduct required with NI trials, and the myth that NI trials always require huge sample sizes. Copyright © 2007 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio, G., Elbourne, D. R., Altman, D. G., Pocock, S. J., Evans, S. J. W., & CONSORT Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.10.1152 · Cited by 1,153
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials
Kaul, S., & Diamond, G. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00011 · Cited by 272
Cited by
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
Sacco, R. L., Diener, H.-C., Yusuf, S., Cotton, D., Ôunpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805002 · Cited by 961
Combating Antimicrobial Resistance: Policy Recommendations to Save Lives
Infectious Diseases Society of America (IDSA) (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir153 · Cited by 733
Key Concepts of Clinical Trials: A Narrative Review
Umscheid, C. A., Margolis, D. J., & Grossman, C. E. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.09.2475 · Cited by 410
Risk factors and interventions with statistically significant tiny effects
Siontis, G. C., & Ioannidis, J. P. (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyr099 · Cited by 80
Bio-creep in non-inferiority clinical trials
Everson‐Stewart, S., & Emerson, S. S. (2010) · Statistics in Medicine · doi:10.1002/sim.4053 · Cited by 64
Schiller, P., Burchardi, N., Niestroj, M., & Kieser, M. (2012) · Trials · doi:10.1186/1745-6215-13-214 · Cited by 53
Feng, J., Emerson, S., & Simon, N. (2021) · Biometrics · doi:10.1111/biom.13379 · Cited by 26
Metadata
- Authors
- Fleming, T. R.
- Venue
- Statistics in Medicine
- Publisher
- Wiley
- Published
- 2007-03-05
- Volume
- 27
- Issue
- 3
- Pages
- 317-332
- ISSN
- 0277-6715 (ISSN-L)
- 1097-0258
- OpenAlex
- W2141102048
- Cited by
- 211
- References
- 4
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.